Swiss Auto Components Stock News

Sandoz Group shareholders approved all proposals at the 2026 AGM, including board re elections and governance roles. Compensation plans for leadership and a dividend payment were endorsed, confirming broad investor backing. The AGM outcome points to continuity in how Sandoz Group is run and how its strategy is overseen. Sandoz Group (SWX:SDZ) held this AGM with the share price at CHF66.62 and a 1 year return of 114.0%. The stock has also posted returns of 4.1% over the past week, 7.6% over...

SaltX recently reported that it has completed the first industrial-scale test period of electrified precalcination of Holcim’s cement raw meal at its ECRC facility in Hofors, Sweden, achieving positive calcination results and operational stability while processing around 20 tonnes per test run. This progress, alongside parallel work on electrified sintering and a fully electrified pilot plant targeted for 2028, highlights Holcim’s push to electrify and decarbonize cement production at an...

Earnings highlight and why it matters now R&S Group Holding (SWX:RSGN) just released its full year 2025 results, with sales of CHF 414.84 million, revenue of CHF 417.53 million, and net income of CHF 58.1 million drawing fresh attention to the stock. See our latest analysis for R&S Group Holding. The latest results appear to have kept momentum strong, with the share price at CHF24.2 and a 7 day share price return of 22.84% building on a 90 day share price return of 55.33%. The 3 year total...

Julius Bär Gruppe (SWX:BAER) is in the spotlight after a series of leadership changes, including the planned departure of finance chief Evie Kostakis and new board responsibilities for incoming non executive director Colin Bell. See our latest analysis for Julius Bär Gruppe. The executive reshuffle comes as the stock shows mixed momentum, with a 4.9% 1 month share price return and a 1 year total shareholder return of 33.7% contrasting with weaker recent quarterly performance. If leadership...

Medacta Group (SWX:MOVE) has stepped into an unusual spotlight after being selected to engineer a load bearing hip implant for a resurrected Tyrannosaurus rex as part of an international dinosaur revival project. See our latest analysis for Medacta Group. While the dinosaur project has put Medacta in the headlines, the CHF153.4 share price sits below its recent peak, with short term share price returns weaker. However, a 1 year total shareholder return of 34.52% still points to solid long...

Avolta (SWX:AVOL) has secured a 15 year food and beverage contract at Jacksonville International Airport in Florida, adding a new airport food hall with four outlets that mix local concepts and national brands. See our latest analysis for Avolta. The Jacksonville contract lands at a time when Avolta’s share price sits at CHF52.2, with a 1 month share price return of 8.70% and a 1 year total shareholder return of 57.10%. This suggests momentum has been building recently despite a weaker 5 year...

It looks like Geberit AG ( VTX:GEBN ) is about to go ex-dividend in the next four days. The ex-dividend date is...

How the Clareon TruPlus launch is feeding into Alcon’s stock story Alcon (SWX:ALC) is back in focus after the U.S. launch of its Clareon TruPlus intraocular lens at the ASCRS meeting, a move that helped spark a 3.96% share price gain. The new monofocal and toric lens expands Alcon’s cataract surgery lineup with extended depth of focus and lower glare. This comes alongside ongoing medical conference presentations that spotlight the product’s clinical profile and potential relevance for...

Galderma Group (SWX:GALD) is back in focus after new clinical data on Sculptra and Restylane in menopause and medication driven weight loss, fresh nemolizumab results in pediatric atopic dermatitis, and the ALASTIN Signature Practices rollout. See our latest analysis for Galderma Group. The latest clinical readouts and the ALASTIN Signature Practices launch come after a mixed year for the shares, with a 5.83% 1 month share price return, a 3.27% 3 month share price decline, and a 1 year total...

Mobimo Holding (SWX:MOBN) confirmed a total distribution of CHF 10.25 per registered share at its 31 March 2026 AGM and elected management consultant Sophie Dubuis to the Board of Directors, developments that shareholders are watching closely. See our latest analysis for Mobimo Holding. These AGM decisions come as the share price sits at CHF 381.0, with a 90 day share price return of 2.28% and a 1 year total shareholder return of 29.59% indicating momentum built more gradually over the longer...

Montana Aerospace (SWX:AERO) just posted its 2025 results, reporting higher sales from its Aerostructures segment along with a small net loss and a completed exit from its Energy business, which leaves it focused on aerospace. See our latest analysis for Montana Aerospace. The latest earnings release and Energy exit came after a weak period for the share price, with a 30 day share price return of an 18.01% decline and a 90 day share price return of a 25.08% decline. However, the 1 year total...

Why Comet Holding Is Back on AI Investors' Radar Comet Holding (SWX:COTN) is back in focus after recent commentary highlighted its exposure to AI driven semiconductor investment, stronger than expected orders for RF generators and inspection systems, and expectations for positive FY 2026 guidance. See our latest analysis for Comet Holding. At a share price of CHF280.0, Comet Holding has seen momentum build recently, with a 30 day share price return of 13.64% and a 1 year total shareholder...

Interest in Holcim (SWX:HOLN) has picked up after partner SaltX reported positive initial results from industrial-scale tests of electrified precalcination of Holcim cement raw meal in Sweden. See our latest analysis for Holcim. The recent electrified precalcination progress comes as Holcim’s share price has risen 12.5% over the past month to CHF72.52, even though the 90 day share price return is a 9.2% decline, while the 1 year total shareholder return of 74.8% and 3 year total shareholder...

Stadler Rail (SWX:SRAIL) has withdrawn its appeal against SBB’s award of a major double deck train contract to Siemens, ending a period of legal uncertainty and confirming the loss of this domestic order. See our latest analysis for Stadler Rail. The withdrawal of the SBB appeal comes at a time when momentum in the share price has picked up in the short term, with a 30 day share price return of 14.72%, yet longer term total shareholder returns, including dividends, remain negative over three...

Readers hoping to buy mobilezone holding ag ( VTX:MOZN ) for its dividend will need to make their move shortly, as the...

UBS Group (SWX:UBSG) is back in focus as traders watch the 29 April 2026 earnings announcement, with recent attention also on its new U.S. national banking license and ongoing legal and advisor-related developments. See our latest analysis for UBS Group. At around CHF32.72, UBS Group’s recent 1 month share price return of 8.6% contrasts with a 90 day share price decline of 14.2%, while the 1 year total shareholder return of 48.2% points to longer term momentum as investors weigh the upcoming...

Luzerner Kantonalbank (SWX:LUKN) has just wrapped up its Q1 2026 reporting period with trailing 12 month revenue of CHF660.6 million, basic EPS of CHF5.97 and earnings growth of 3.1% over the past year. Over the last year, revenue has moved from CHF650.5 million to CHF660.6 million, while net income excluding extra items has gone from CHF286.6 million to CHF295.5 million, with net profit margin edging up to 44.7% from 44.1%. This puts the focus firmly on how sustainably those margins can be...

Westcoast integration gives investors fresh context for ALSO Holding ALSO Holding (SWX:ALSN) is back in focus after its acquired unit Westcoast reported a stronger first quarter in 2026 than in 2025, highlighting progress in integration, cloud operations and logistics synergies. See our latest analysis for ALSO Holding. Despite the positive integration news, ALSO Holding’s share price, at CHF147.4, sits well below where it started the year. It has a year to date share price return of 31.6%...

ABB (SWX:ABBN) has drawn attention after becoming one of the most actively traded stocks on the SIX Swiss Exchange, with ETF driven demand for robotics and automation coinciding with anticipation around its April 22 earnings update. See our latest analysis for ABB. At a share price of CHF70.8, ABB has seen a 7 day share price return of 7.53% and a year to date share price return of 15.61%. Its 1 year total shareholder return of 74.47% points to strong momentum that recent ETF flows and...

It looks like BVZ Holding AG ( VTX:BVZN ) is about to go ex-dividend in the next 3 days. The ex-dividend date is...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Bossard...

UBS Group (SWX:UBSG) has secured approval for a US national banking licence, expanding its ability to offer banking services to US wealth management clients. A US court has declined to clarify the scope of a longstanding Holocaust era settlement involving UBS, leaving questions over potential future claims. UBS has executed a $500m private credit structured finance transaction backed by interests in private credit funds. UBS Group, trading at CHF32.41, is coming into these developments...

Q4 earnings beat puts INFICON Holding (SWX:IFCN) in focus INFICON Holding (SWX:IFCN) is back on investors’ radar after reporting a Q4 2025 earnings per share beat of 85.33% versus expectations, helped by cost controls and operational discipline despite a slight revenue miss. See our latest analysis for INFICON Holding. The Q4 surprise appears to be feeding into sentiment, with the 7 day share price return of 5.50% and a 1 day share price return of 1.27% lifting the stock to CHF111.2. A 1 year...

C4 Therapeutics recently announced a collaboration with Roche to develop degrader-antibody conjugates for oncology, while Roche also launched its cobas MPX-E blood screening assay in CE-mark accepting countries, consolidating HIV and hepatitis virus detection into a single high-throughput test. Together, these moves underline Roche’s push to pair next-generation cancer modalities with advanced diagnostics that can improve laboratory efficiency and transfusion safety worldwide. We’ll now...